Edwards Lifesciences Corporation revised earnings guidance for the full year of 2022. For total Edwards, the company now expects full year 2022 sales of $5.35 to $5.55 billion. The company now expects full year adjusted EPS guidance at the bottom end of its original guidance range of $2.50 to $2.65, representing double-digit growth over 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.29 USD | -0.43% |
|
-0.96% | +14.48% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.48% | 52.6B | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.03% | 64.02B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B | |
+23.08% | 31.1B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022